ESAs to treat anemia—balancing the risks and benefits
Author:
- 1 September 2009
- journal article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 6 (9) , 500-502
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trialsThe Lancet, 2009
- Erythropoietin in Cancer PatientsAnnual Review of Medicine, 2009
- Erythropoiesis-Stimulating Agents in OncologyJournal of the National Comprehensive Cancer Network, 2008
- Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled StudyJournal of Clinical Oncology, 2008
- Erythropoietin or Darbepoetin for patients with cancer2006
- Recombinant Human Erythropoietins and Cancer Patients: Updated Meta-Analysis of 57 Studies Including 9353 PatientsJNCI: Journal of the National Cancer Institute, 2006
- Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival StudyJournal of Clinical Oncology, 2005
- Recombinant Human Erythropoietin and Overall Survival in Cancer Patients: Results of a Comprehensive Meta-analysisJNCI: Journal of the National Cancer Institute, 2005